Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SpePharm Holding has announced the granting of national approvals of Loramyc in the UK, Denmark, Germany, Belgium, The Netherlands, Luxembourg, Finland and Sweden, as well as in Spain under the trade name Sitamic.
Subscribe to our email newsletter
SpePharm’s Loramyc 50mg, a muco-adhesive buccal tablet of miconazole, is indicated for the treatment of oropharyngeal candidiasis (OPC) in immunocompromised patients. At the same time, Loramyc has been launched in the UK and will be promoted in the secondary care setting mostly to cancer and HIV/AIDS patients suffering from OPC.
Jean-Francois Labbe, president and CEO of SpePharm, said: “Following marketing approval and this initial launch in the UK, further launches of Loramyc will follow as other national marketing authorizations are granted, and SpePharm continues to aggressively put in place its sales and marketing infrastructure throughout Europe.”